Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MANNATECH, INCORPORATED

(MTEX)
  Report
Delayed Nasdaq  -  03:38 2022-12-01 pm EST
22.50 USD   +0.72%
11/14Mannatech Inc : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/11Mannatech Declares Third Quarter 2022 Dividend
BU
11/11Mannatech, Incorporated Announces Third Quarter Dividend, Payable on December 28, 2022
CI
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mannatech, Inc. : Mannatech Presents Glyconutrient Science at the 10th Jenner Glycobiology and Medicine Symposium

04/04/2012 | 12:10pm EST

Mechanisms that might contribute to the cognitive benefits of Mannatech's Ambrotose« polysaccharides are presented

Mannatech, Incorporated (NASDAQ: MTEX), the leading innovator and provider of nutritional supplements based on Real Food Technology® solutions, announced the presentation of product research at the prestigious 10th Jenner Glycobiology and Medicine Symposium, which was held in The Hague, the Netherlands, March 31-April 3, 2012. The pre-clinical study showed that intake of Advanced Ambrotose® powder had positive effects in the brain on the expression of genes associated with the regulation of learning, memory and mood.*(1)

"We were pleased to be invited to present our science at this prestigious event," said Dr. Robert Sinnott, CEO and Chief Science Officer at Mannatech. "The United Kingdom's Royal Society of Medicine has been hosting these meetings--devoted to providing a forum for scientists and clinicians to disseminate the findings of current leading-edge research in both novel and classic fields of glycobiology--for over 20 years. Our interesting, preliminary research presents findings that are highly compatible with multiple controlled human clinical studies, which indicate that intake of Ambrotose® products provides significant cognitive benefits to healthy adults."*

The study was authored by Dr. Erika N. Nelson, Jane Ramberg and Dr. Sinnott. Dr. Nelson earned her BS in Genetics from the University of Kansas in Lawrence and went on to obtain her PhD in Neuroscience at the University of Texas Southwestern Medical Center in Dallas. She has published a number of papers on neurodevelopmental disorders and brain epigenetics. A candidate for a Masters of Business Administration at the University of Texas at Dallas, Dr. Nelson is also a consultant for Mannatech. Jane Ramberg is Director of Product Substantiation at Mannatech.

The 10th Jenner Glycobiology and Medicine Symposium brought together scientists from around the world, including many thought leaders in the field of glycobiology. More information about the meeting can be found here: http://www.rsm.ac.uk/jenner10/.

Individuals interested in Mannatech's products or exploring its business opportunity are encouraged to learn more at Mannatech.com.

About Mannatech

Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. Mannatech is dedicated to its platform of Social Entrepreneurship based on the foundation of promoting, aiding and optimizing nutrition where it is needed most around the world. Mannatech's proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech Republic, the Republic of Korea, Mexico and Namibia. For more information, visit Mannatech.com.

Please note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "believe," "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain Associates and Members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

1. Nelson EN, Ramberg JE, Sinnott RA. Brain-specific effects of Ambrotose® products: a preliminary animal study to investigate cognitive benefits found in humans. Poster Presentation at the 10th Jenner Glycobiology and Medicine Symposium, The Hague, the Netherlands, March 31-April 3, 2012.

Mannatech, Incorporated
Brett Duncan, 972-471-7367
bduncan@mannatech.com


ę Business Wire 2012
All news about MANNATECH, INCORPORATED
11/14Mannatech Inc : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/11Mannatech Declares Third Quarter 2022 Dividend
BU
11/11Mannatech, Incorporated Announces Third Quarter Dividend, Payable on December 28, 2022
CI
11/08Mannatech, Incorporated Reports Earnings Results for the Third Quarter and Nine Months ..
CI
11/08MANNATECH INC Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/08Mannatech Reports Third Quarter End 2022 Financial Results
BU
11/08Earnings Flash (MTEX) MANNATECH INCORPORATED Posts Q3 Revenue $35.5M
MT
11/07Mannatech is Reinventing Hydration Introduces Exclusive Blue Water
AQ
11/04Mannatech is Reinventing Hydration, Introduces Exclusive Blue Water
BU
11/04Mannatech, Incorporated Introduces Exclusive Blue Water
CI
More news
Financials (USD)
Sales 2021 160 M - -
Net income 2021 9,84 M - -
Net cash 2021 18,0 M - -
P/E ratio 2021 8,14x
Yield 2021 1,98%
Capitalization 41,5 M 41,5 M -
EV / Sales 2020 0,17x
EV / Sales 2021 0,35x
Nbr of Employees 247
Free-Float 37,6%
Chart MANNATECH, INCORPORATED
Duration : Period :
Mannatech, Incorporated Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MANNATECH, INCORPORATED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Managers and Directors
Alfredo Bala President & Chief Executive Officer
David A. Johnson Chief Accounting Officer
J. Stanley Fredrick Director
Larry A. Jobe Independent Director
Robert A. Toth Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
MANNATECH, INCORPORATED-41.28%42
ZHEJIANG NHU COMPANY LTD.-24.04%8 548
BY-HEALTH CO., LTD.-26.19%4 777
BALCHEM CORPORATION-16.49%4 525
THE SIMPLY GOOD FOODS COMPANY-5.17%3 950
BELLRING BRANDS, INC.-12.69%3 372